JP2021521856A5 - - Google Patents
Info
- Publication number
- JP2021521856A5 JP2021521856A5 JP2020560400A JP2020560400A JP2021521856A5 JP 2021521856 A5 JP2021521856 A5 JP 2021521856A5 JP 2020560400 A JP2020560400 A JP 2020560400A JP 2020560400 A JP2020560400 A JP 2020560400A JP 2021521856 A5 JP2021521856 A5 JP 2021521856A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024182581A JP7844582B2 (ja) | 2018-04-27 | 2024-10-18 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663545P | 2018-04-27 | 2018-04-27 | |
| US62/663,545 | 2018-04-27 | ||
| PCT/US2019/029082 WO2019210042A1 (en) | 2018-04-27 | 2019-04-25 | Expression of foxp3 in edited cd34+ cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024182581A Division JP7844582B2 (ja) | 2018-04-27 | 2024-10-18 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021521856A JP2021521856A (ja) | 2021-08-30 |
| JPWO2019210042A5 JPWO2019210042A5 (https=) | 2022-11-25 |
| JP2021521856A5 true JP2021521856A5 (https=) | 2022-11-25 |
| JP7575950B2 JP7575950B2 (ja) | 2024-10-31 |
Family
ID=68294731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560400A Active JP7575950B2 (ja) | 2018-04-27 | 2019-04-25 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
| JP2024182581A Active JP7844582B2 (ja) | 2018-04-27 | 2024-10-18 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024182581A Active JP7844582B2 (ja) | 2018-04-27 | 2024-10-18 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11713459B2 (https=) |
| EP (1) | EP3784690A4 (https=) |
| JP (2) | JP7575950B2 (https=) |
| CN (1) | CN112218882A (https=) |
| AU (2) | AU2019261438B2 (https=) |
| CA (1) | CA3091688A1 (https=) |
| IL (1) | IL277039A (https=) |
| SG (1) | SG11202007878UA (https=) |
| WO (1) | WO2019210042A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110139675B (zh) | 2016-10-31 | 2023-09-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 用具有工程化稳定的内源性foxp3基因表达的cd4t细胞治疗自身免疫疾病的方法 |
| CA3091491A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of human foxp3 in gene edited t cells |
| US11713459B2 (en) * | 2018-04-27 | 2023-08-01 | Seattle Children's Hospital | Expression of FOXP3 in edited CD34+ cells |
| KR20210116531A (ko) * | 2019-01-18 | 2021-09-27 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 영양 장애형 표피 수포증 치료약 |
| EP3973067A1 (en) * | 2019-05-21 | 2022-03-30 | Sangamo Therapeutics, Inc. | Controlled transgene expression in regulatory t cells |
| AU2020304057A1 (en) * | 2019-06-27 | 2022-01-27 | Benaroya Research Institute At Virginia Mason | Artificial antigen-specific immunoregulatory t (airt) cells |
| US20220380727A1 (en) | 2019-11-08 | 2022-12-01 | Sangamo Therapeutics, Inc. | Generation of engineered regulatory t cells |
| WO2021144692A1 (en) * | 2020-01-14 | 2021-07-22 | Crispr Therapeutics Ag | Methods for increased efficiency of homology-directed repair |
| EP4103591A4 (en) | 2020-02-13 | 2024-09-04 | The Board of Trustees of the Leland Stanford Junior University | Crispr-based foxp3 gene engineered t cells and hematopoietic stem cell precursors to treat ipex syndrome patients |
| WO2022093884A1 (en) * | 2020-10-27 | 2022-05-05 | Pact Pharma, Inc. | Compositions and methods for the treatment of cancer using next generation engineered t cell therapy |
| CN112851794B (zh) * | 2021-02-04 | 2023-05-23 | 苏州铂维生物科技有限公司 | 一种基于cd271的抗原表位及其应用 |
| GB202113674D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
| GB202113673D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1430124B1 (en) | 2000-09-20 | 2013-11-06 | EMD Millipore Corporation | Artificial ubiquitous chromatin opening elements (ucoe) |
| US7507542B2 (en) | 2001-05-08 | 2009-03-24 | Ucb Sa | Method for regulating immune function using the FOXP3 protein |
| GB0614536D0 (en) | 2006-07-21 | 2006-08-30 | Metcalfe Susan M | Methods of controlling cellular response to LIF |
| EP2064350B1 (en) * | 2006-11-27 | 2013-01-02 | Ludwig Institute for Cancer Research Ltd. | Expression of foxp3 by cancer cells |
| EP2126054B1 (en) | 2007-01-31 | 2016-07-06 | Yeda Research And Development Company Limited | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| WO2008101272A1 (en) | 2007-02-21 | 2008-08-28 | Women's And Children's Health Research Institute Inc | Method for obtaining treg-cells |
| US8158596B2 (en) | 2007-05-11 | 2012-04-17 | The Regents Of The University Of Michigan | Materials and methods for FOXP3 tumor suppression |
| WO2008154399A1 (en) | 2007-06-08 | 2008-12-18 | The Trustees Of The University Of Pennsylvania | Foxp3 oligomerization and intermolecular interactions |
| JP2011503232A (ja) | 2007-11-20 | 2011-01-27 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 免疫応答の調節 |
| CA2717166A1 (en) | 2008-03-03 | 2009-09-19 | Converge Biotech Inc. | Methods of modulating t cell-dependent immune responses |
| WO2012018930A1 (en) | 2010-08-03 | 2012-02-09 | University Of Miami | Methods of isolating and expanding human t regulatory cells and uses thereof for cellular therapy |
| WO2014180943A1 (en) | 2013-05-08 | 2014-11-13 | Vib Vzw | Mcl-1 as critical regulator of foxp3+ regulatory t cell survival, and use thereof to treat severe immune disorders |
| MX2015015638A (es) | 2013-05-13 | 2016-10-28 | Cellectis | Metodos para diseñar celulas t altamente activas para inmunoterapia. |
| ES2883131T3 (es) * | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| ES3063961T3 (en) | 2014-02-14 | 2026-04-21 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| EP3119897A1 (en) | 2014-03-21 | 2017-01-25 | Cellectis | Engineering mammalian genome using dna-guided argonaute interference systems (dais) |
| KR101835554B1 (ko) | 2014-06-24 | 2018-04-19 | 서울대학교 산학협력단 | C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법 |
| CN107250373A (zh) | 2015-01-12 | 2017-10-13 | 麻省理工学院 | 通过微流体递送实现的基因编辑 |
| WO2016123578A1 (en) | 2015-01-30 | 2016-08-04 | The Regents Of The University Of California | Protein delivery in primary hematopoietic cells |
| EP3294342A4 (en) * | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| US11499168B2 (en) | 2016-04-25 | 2022-11-15 | Universitat Basel | Allele editing and applications thereof |
| WO2018031762A1 (en) | 2016-08-10 | 2018-02-15 | Duke University | Compositions, systems and methods for programming immune cell function through targeted gene regulation |
| WO2018035141A1 (en) | 2016-08-16 | 2018-02-22 | Bluebird Bio, Inc. | Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use |
| WO2018073391A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| CA3041831A1 (en) | 2016-10-27 | 2018-05-03 | Intima Bioscience, Inc. | Viral methods of making genetically modified cells |
| CN110139675B (zh) | 2016-10-31 | 2023-09-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 用具有工程化稳定的内源性foxp3基因表达的cd4t细胞治疗自身免疫疾病的方法 |
| JP7206214B2 (ja) | 2016-12-13 | 2023-01-17 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法 |
| CN109797171A (zh) * | 2017-05-08 | 2019-05-24 | 北京东方略细胞技术有限公司 | 经修饰的t细胞、其制备方法及用途 |
| EP3672617A4 (en) | 2017-08-22 | 2021-06-23 | The Regents of the University of California | LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES |
| US11713459B2 (en) * | 2018-04-27 | 2023-08-01 | Seattle Children's Hospital | Expression of FOXP3 in edited CD34+ cells |
| CA3091491A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of human foxp3 in gene edited t cells |
| WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
-
2019
- 2019-04-25 US US16/981,223 patent/US11713459B2/en active Active
- 2019-04-25 CN CN201980028370.7A patent/CN112218882A/zh active Pending
- 2019-04-25 JP JP2020560400A patent/JP7575950B2/ja active Active
- 2019-04-25 CA CA3091688A patent/CA3091688A1/en active Pending
- 2019-04-25 AU AU2019261438A patent/AU2019261438B2/en active Active
- 2019-04-25 WO PCT/US2019/029082 patent/WO2019210042A1/en not_active Ceased
- 2019-04-25 EP EP19793428.4A patent/EP3784690A4/en active Pending
- 2019-04-25 SG SG11202007878UA patent/SG11202007878UA/en unknown
-
2020
- 2020-08-31 IL IL277039A patent/IL277039A/en unknown
-
2023
- 2023-06-16 US US18/336,276 patent/US20240117352A1/en active Pending
-
2024
- 2024-10-18 JP JP2024182581A patent/JP7844582B2/ja active Active
- 2024-11-22 AU AU2024266824A patent/AU2024266824A1/en active Pending